miR-506 can restore chemosensitivity to 5-fluorouracil (5-FU) in drug-resistant cancer cells by downregulating polypyrimidine tract-binding protein 1 (PTBP1) expression and suppressing glycolytic activity. Here, PTBP1 is linked to cancer.